Trials / Completed
CompletedNCT03317483
DEB-TACE Treatment in 367 Liver Cancer Patients
The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-eluting Beads Transarterial Chemoembolization in 367 Patients With Liver Cancer: a Multiple-center Cohort Study (CTILC Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 367 (actual)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Introduction:The drug-eluting beads transarterial chemoembolization (DEB-TACE) is introduced to better improve efficacy and reduce the systemic toxicity in liver cancer patients on account of its higher intratumoral chemotherapeutic drug concentration and reduced drug infiltration into systemic circulation. This study aimed to investigate the efficacy, safety and prognostic factors of DEB-TACE treatment in Chinese patients with liver cancer. Hypothesis:DEB-TACE illustrates a better treatment response, progression free survival (PFS), overall survival (OS) and less common adverse events (AEs) in liver cancer patients. Objective: to investigate the efficacy, safety and prognostic factors of DEB-TACE treatment in Chinese patients with liver cancer.
Conditions
Timeline
- Start date
- 2015-11-12
- Primary completion
- 2016-11-04
- Completion
- 2016-12-28
- First posted
- 2017-10-23
- Last updated
- 2017-10-23
Source: ClinicalTrials.gov record NCT03317483. Inclusion in this directory is not an endorsement.